Search
Two pivotal studies published in the New England Journal of Medicine and conducted by Memorial Sloan Kettering researchers offer proof of better treatment options for patients with advanced renal cell carcinoma (RCC), the most common form of kidney cancer.
Catch up with some of the patients we got to know in 2017.
At Memorial Sloan Kettering Cancer Center, more than half of patients with gallbladder cancer are diagnosed incidentally following elective cholecystectomy for assumed benign disease. The traditional treatment approach for these patients is re-resection to achieve a cure.
Read our suggestions for getting through the holiday season while facing cancer.
Cancer knows no borders or languages. For most people newly diagnosed with cancer, it’s hard enough trying to understand their diagnosis, treatment options, and the life changes that lie ahead without also having to contend with a language barrier. The challenges are even more daunting for people facing an advanced, life-threatening disease.
El cáncer no conoce fronteras ni idiomas. Para la mayoría de las personas recién diagnosticadas con cáncer, ya es bastante difícil tratar de comprender su diagnóstico, las opciones de tratamiento y los cambios de vida que les esperan sin tener que lidiar con una barrera del idioma. Los desafíos son aún más desalentadores para las personas que enfrentan una enfermedad avanzada y potencialmente mortal.
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
Our students’ research is recognized with the Geoffrey Beene Graduate Student Fellowships, the Catell Fellowship, the Olayan Fellowship, and the Palestin Fellowship.
Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) surveillance. However, if patients with a high risk of brain metastasis after surgical resection can be identified, surveillance and prophylactic treatment with CNS-directed therapies may improve outcomes.
The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to selpercatinib (Retevmo™) for lung and thyroid cancers with RET (REarranged during Transfection) gene mutations or fusions.